Continuous Glucose Monitor
Signos excels in safety (FDA clearance, established Dexcom tech safe in 100+ diabetes trials) and quality (transparent hardware/app integration), but effectiveness limited by absence of RCTs proving weight loss (only observational LST correlation PMID 39078656; ongoing NCT05121844). Matches 'continuous wear' protocol but evidence for non-diabetics weak vs diabetes (strong meta-analyses). Overall balanced for metabolic tracking, not proven weight loss tool. Value competitive at $129/mo vs $200+ p
FDA-cleared Signos CGM Program uses accurate Dexcom Stelo for real-time glucose insights aiding metabolic awareness. Safe per device standards and predicate trials, but lacks RCTs confirming weight loss (observational LST correlation only). Good for tracking, monitor ongoing trials.